thienopyridine

thienopyridine

(thĪ-en-ō'pir'a-dēn),
One of a group of compounds, including ticlopidine and clopidogrel, which prevent platelet aggregation.

thienopyridine

(thi?e-no?pir'a-den?)
Any of a group of drugs that block the aggregation of platelets. Drugs in this class are used to prevent arterial clotting and are effective in the prevention of strokes, heart attacks, stent thromboses, and peripheral arterial disease. Examples include prasugrel, ticlopidine, and clopidogrel. Their most common side effect is bleeding. Synonym: adenosine diphosphate antagonist; adenosine diphosphate receptor antagonist
Mentioned in ?
References in periodicals archive ?
3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) and molecular docking study of thienopyrimidine and thienopyridine derivatives to explore structural requirements for aurora-B kinase inhibition.
Two case reports evaluated use of prasugrel as an alternative antiplatelet agent and indicate that the arthralgia ADE may not be a thienopyridine class effect [5, 6].
The newest member of the P2Y12 inhibitors is ticagrelor, which is not a thienopyridine and, however, demonstrates a superior pharmacological profile than clopidogrel.
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
The COMPASS findings follow a 2012 published report from the ATLAS ACS 2-TIMI 51 trial showing that treatment with the same low-dose rivaroxaban regimen plus aspirin and a thienopyridine (clopidogrel or ticlopidine) reduced the same combined triple endpoint by a statistically significant 16%, compared with aspirin and a thienopyridine alone, in patients with a recent acute coronary syndrome event (N Engl J Med.
Clopidogrel is a thienopyridine derivative, used to inhibit the formation of blood clots in coronary artery disease, peripheral vascular disease, and stroke.
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Clopidogrel is a second-generation thienopyridine antiplatelet drug which exerts its effect by the inhibition of the platelet's purinergic receptor P2Y12 preventing adenosine diphosphate (ADP) from stimulating it.
Inhibitors of gp IIb/IIIa receptor are potent anti-platelet agents and act by a mechanism distinct from that of aspirin or thienopyridine platelet inhibitors.
For people with NVAF following PCI, guidelines recommend "triple therapy", which is a combination of dual antiplatelet therapy (clopidogrel or another thienopyridine plus aspirin) and anticoagulation therapy with a vitamin K antagonist (warfarin), but this regimen comes with recognized increased rates of major bleeding, including intracranial bleeding.